A field of gold and pearl molecules on a warm white ground

Your respiratory program, from molecule to approval

Our development team includes people who contributed to BEVESPI AEROSPHERE® and BREZTRI AEROSPHERE™, approved in the U.S., EU, China and Japan.

1

From study design through submission to approval

Development platform

Our team has collectively contributed to more than 50 approved products or label expansions across the globe over the past 30 years.

Since 2020
The finished path: the molecule on an approved inhaler beside frosted-glass lungs in the Approval lane
FDAEMAPMDAMHRAHealth CanadaTGANMPA
  1. Pre-clinical
  2. Phase 1
  3. Phase 2
  4. Phase 3
  5. Registration
  6. Approval

Our team has collectively contributed to more than 50 approved products or label expansions across the globe over the past 30 years.

  1. 1Design

    Our specialists design an efficient clinical program to support regional or global registration, with customized trials built on scientifically sound methods and regulatory guidelines from protocol design onward.

    Study design, protocol design, clinical program design

  2. 2Develop

    We manage your trials, tap an extensive network of clinical trial sites, recruit patients with precision and keep trial data accurate and secure, with insights that support timely decisions.

    Clinical trial management, site and patient recruitment, data management and analysis

  3. 3Deliver

    We prepare comprehensive submissions for global health authorities and negotiate with them through to approval. Our team has led major sponsor inspections in the U.S., EU, China and Japan.

    Regulatory submissions to FDA, EMA, PMDA, MHRA, Health Canada, TGA and NMPA

2

Run by the people who did it before

DevPro was founded by former Pearl Therapeutics and AstraZeneca executives. Together our team brings over a century of shared clinical development experience.

Founders
  • Colin Reisner, MD, Founder & CEO

    Colin Reisner, MD

    Founder & CEO

    Previously CEO of Pearl Therapeutics and SVP at AstraZeneca

  • Earl St. Rose, Founder & COO

    Earl St. Rose

    Founder & COO

    Previously VP at Pearl Therapeutics and AstraZeneca

  • Pramila Monte, Founder & Chief Strategy and Clinical Development Officer

    Pramila Monte

    Founder & Chief Strategy and Clinical Development Officer

    Over 21 years in clinical safety and health authority inspections

  • Catherine Pelc, Founder & Chief People and Business Operations Officer

    Catherine Pelc

    Founder & Chief People and Business Operations Officer

    Over 26 years in clinical operations

  • Kim Rossman, Founder & Chief Clinical Execution and Delivery Officer

    Kim Rossman

    Founder & Chief Clinical Execution and Delivery Officer

    Over 29 years in clinical trial execution

3Respiratory focus

The respiratory conditions we work in

Our work is respiratory focused. Alongside our own albuterol inhaler, we partner with Uniquity Bio on Phase 2 asthma and COPD studies of its monoclonal antibody.

  • 01COPD
  • 02Asthma
  • 03Idiopathic pulmonary fibrosis
  • 04Progressive pulmonary fibrosis
  • 05Cystic fibrosis
  • 06Pulmonary hypertension
  • 07Alpha-1 antitrypsin deficiency
Scientific advisors

7physicians at leading research institutes and medical schools in the U.S. and Europe

  • Gary T. Ferguson, MDDirector, Pulmonary Research Institute of Southeast Michigan
  • MeiLan K. Han, MD, MSDirector, Michigan Airways Program, University of Michigan Health System
  • Fernando J. Martinez, MD, MSChief, Pulmonary and Critical Care Medicine, Weill Cornell Medical College
  • Sydney Montesi, MDAssistant Professor of Medicine, Harvard Medical School
  • Klaus F. Rabe, MDProfessor of Pulmonary Medicine, University of Kiel
  • Lisa Saiman, MDProfessor of Pediatrics, Columbia University Medical Center
  • David S. Wilkes, MDDean, University of Virginia School of Medicine
4

Ways to partner with us

1Your development company

We partner as a stand-alone development company, running full development activities from concept through regulatory approvals.

Full development, concept to approval

2Co-development

If you are a pharma company or a venture capital investor, we can jointly identify and develop new molecular entities with you.

For pharma companies and VCs

Partnering with our experienced team on our proven clinical development platform results in de-risked assets, accelerated timelines, lower costs and an increased likelihood of positive outcomes.

Discuss your program
5

Development pipeline

We develop cutting-edge products that address high unmet medical needs. Our current clinical trials are in Phase 1 and Phase 2.

Indication
Cystic fibrosisCFPhase 1
AsthmaPhase 2
COPDPhase 2
Idiopathic pulmonary fibrosisIPFPhase 2
Progressive pulmonary fibrosisPPFPhase 2

Product names confidential.

Contact

A:Basking Ridge, New Jersey

Discuss your program

Tell us about your molecule, your indication and where it is in development.